Immediate Impact

92 standout
Sub-graph 1 of 21

Citing Papers

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
2024 Standout
8 intermediate papers

Works of Martin Goros being referenced

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease
2013

Author Peers

Author Last Decade Papers Cites
Martin Goros 165 71 248 75 9 432
Margit Gogg-Kamerer 181 63 179 59 14 447
Michael Dudek 164 44 275 75 11 445
Hisao Ezaki 130 29 259 135 12 424
Michael Pimienta 193 54 244 47 12 467
Natalie Thorn 202 22 294 66 7 442
Jennifer Demieville 114 82 216 176 16 507
Yoshiyuki Sakamaki 168 64 285 115 5 472
Shamini G. Shekeran 167 67 115 37 11 392
Kristin Wahl 165 50 227 149 10 511
Kohji Otogawa 125 45 179 148 8 390

All Works

Loading papers...

Rankless by CCL
2026